Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Recruiting 4Active not recruiting 4Completed 2Unknown 1

Sponsor Class

OTHER 2NIH 2

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 23Gastrointestinal 8Endocrine 8Sarcoma 7Thoracic 5Head & Neck 5NET 4Gynecologic 3Dermatologic 2CNS 2Breast 2Tumor-Agnostic 1

Conditions

Neuroendocrine Tumors 4Carcinoma, Neuroendocrine 2Small Cell Lung Carcinoma 1Non functioning pancreatic endocrine tumor 1Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 13Magnetic Resonance Spectroscopy 6Specimen Handling 5pembrolizumab 4cabozantinib 4Nivolumab 4Octreotide 3Lutetium-177 3Ipilimumab 3Everolimus 3lenvatinib 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Temozolomide 2Phantoms, Imaging 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2toripalimab 1tislelizumab 1telotristat ethyl 1surufatinib 1peposertib 1pazopanib 1pasireotide 1fludarabine phosphate 1fludarabine 1entrectinib 1copper dotatate CU-64 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × cabozantinib × NET × Clear all
NCT03375320 2026-06-03

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

National Cancer Institute (NCI)

Phase 3 Active not recruiting
298 enrolled 14 charts 1 FDA
EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT04079712 2026-04-13

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
17 enrolled 12 charts
EndocrineNETThoracic

Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Small Cell Lung Carcinoma

NCT05249114 2026-04-13

Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors

Providence Health & Services

Phase 1 Active not recruiting
6 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04524208 2024-08-13

CABONEN

University Medical Center Goettingen

Phase 2 Active not recruiting
45 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡